Use your antibodies-online credentials, if available.
No Products on your Comparison List.
Your basket is empty.
Find out more
CLEC9A is a group V C-type lectin-like receptor (CTLR) that functions as an activation receptor and is expressed on myeloid lineage cells (Huysamen et al., 2008 [PubMed 18408006]).[supplied by OMIM, Aug 2008].. Additionally we are shipping CLEC9A Kits (10) and CLEC9A Proteins (7) and many more products for this protein.
Showing 10 out of 116 products:
Data indicate that blood dendritic cell antigen 3 BDCA3 (show THBD Antibodies)(+) and C-type lectin (show MBL2 Antibodies) domain family 9, member A (show CXCL14 Antibodies) CLEC9A(+) dendritic cells (DC) are of major importance in the induction of anti-viral and anti-tumor immunity.
Activated dendritic cell subsets expressing CD141 (show THBD Antibodies)/CLEA9A/CD1c (show CD1C Antibodies), likely recruited into the tubulointerstitium, are positioned to play a role in the development of fibrosis and, thus, progression to chronic kidney disease.
study showsn that the DNGR-1 ligand is preserved from yeast to man and corresponds to the F-actin component of the cellular cytoskeleton; identification of F-actin as a DNGR-1 ligand suggests that cytoskeletal exposure is a universal sign of cell damage that can be targeted by the innate immune system to initiate immunity
High expression of DNGR-1 specifically and universally identifies a unique dendritic cells subset in mouse and humans.
propose that Clec9A provides targeted recruitment of the adaptive immune system during infection and can also be utilized to enhance immune responses generated by vaccines.
Data show that CLEC9A is only expressed on immature BDCA3 (show THBD Antibodies)(+) myeloid dendritic cells (mDCs).
For production of cytotoxic T cells, transge (show LY75 Antibodies)nic DEC-205 and Clec9A, but (show CLEC12A Antibodies)not Clec12A, are effective targets for antibody-mediated delivery of antigens for vaccination, although only in the presence of adjuvants.
A population of human dendritic cells (DC) that expresses DNGR-1 (CLEC9A) and high levels of BDCA3 (show THBD Antibodies) and resembles mouse CD8alpha+ DCs in phenotype and function, is characterized.
The paper cited (J Clin Invest. 2008 Jun;118(6):2098-110) is the first characterization of human and mouse CLEC9A (a.k.a DNGR-1)
CLEC9A functions as an activation receptor
Study found presence of DNGR-1 in the brain, providing a potential marker for the study of a specific denditritic brain cell subset
A dependence on DNGR-1 for RSV-specific CD8 (show CD8A Antibodies)(+) T-cell responses was observed.
Genetic tracing of DNGR-1 expression history specifically marks cells traditionally ascribed to the dendritic cells lineage, and this restriction is maintained after inflammation.
Clec9A-positive dendritic cells control susceptibility of mice to experimental cerebral malaria.
Loss of DNGR-1 impaired the CD8 (show CD8A Antibodies) positive lymphocyte cytotoxic response to vaccinia virus, especially against those virus strains that are most dependent on cross-presentation.
DNGR-1 regulated cross-priming in non-infectious settings such as immunization with antigen-bearing dead cells, as well as in highly immunogenic situations such as infection with herpes simplex virus type 1.
Data show that targeting of antigen to Clec9A in batf3 (show BATF3 Antibodies) null mice produced enhanced antibody responses.
For production of cytotoxic T cells, DEC-205 (show LY75 Antibodies) and Clec9A, but not Clec12A (show CLEC12A Antibodies), are effective targets for antibody-mediated delivery of antigens for vaccination, although only in the presence of adjuvants.
CLEC9A is a group V C-type lectin-like receptor (CTLR) that functions as an activation receptor and is expressed on myeloid lineage cells (Huysamen et al., 2008
C-type lectin domain family 9 member A
, dendritic cell natural killer lectin group receptor 1